Keros Therapeutics, Inc. (KROS) Bundle
An Overview of Keros Therapeutics, Inc. (KROS)
General Summary of Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for rare diseases. The company specializes in developing therapies targeting hematological and musculoskeletal disorders.
| Company Detail | Information |
|---|---|
| Headquarters | Lexington, Massachusetts |
| Founded | 2015 |
| Key Product | Lytvora (mitapivat) |
Financial Performance in Latest Reporting Period
Financial data for Keros Therapeutics in the most recent quarter:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $39.4 million |
| Net Loss | $36.2 million |
| Cash and Investments | $341.8 million |
Industry Leadership
Keros Therapeutics focuses on developing therapies for rare diseases with significant unmet medical needs.
- Specializes in hematological disorders
- Developing treatments for rare genetic conditions
- Focused on precision medicine approaches
Key research areas include:
- Pyruvate kinase deficiency treatment
- Rare bone marrow failure syndromes
- Musculoskeletal disorder therapies
| Research Pipeline | Current Stage |
|---|---|
| Mitapivat | FDA-approved for pyruvate kinase deficiency |
| KER-050 | Phase 2 clinical trials |
| KER-047 | Preclinical development |
Mission Statement of Keros Therapeutics, Inc. (KROS)
Mission Statement of Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. focuses on developing transformative therapies for rare hematologic and oncologic disorders.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Rare Disease Research | Hematologic Disorders | 2 primary drug development programs |
| Therapeutic Innovation | Precision Medicine | $108.4 million R&D investment in 2023 |
| Patient Impact | Unmet Medical Needs | 3 clinical-stage therapeutic candidates |
Research and Development Strategy
Keros Therapeutics targets specific molecular pathways in rare diseases.
- KER-050 for bone marrow failure conditions
- KER-047 for anemia treatment
- KER-012 for oncologic interventions
Financial Performance Metrics
| Financial Indicator | 2023 Value |
|---|---|
| Total Revenue | $32.1 million |
| Net Loss | ($65.2 million) |
| Cash and Investments | $361.4 million |
Clinical Development Milestones
Keros maintains a focused pipeline of therapeutic candidates.
- 2 Phase 2 clinical trials in progress
- 1 Phase 1 clinical trial ongoing
- FDA Fast Track designation for KER-050
Vision Statement of Keros Therapeutics, Inc. (KROS)
Keros Therapeutics Vision Statement Analysis (2024)
Strategic Vision FrameworkKeros Therapeutics, Inc. (NASDAQ: KROS) maintains a focused vision centered on advancing rare hematological and bone marrow disorders treatment.
Vision Components
Therapeutic Innovation Priorities| Focus Area | Key Priorities | Development Stage |
|---|---|---|
| Rare Blood Disorders | Precision Therapeutics | Phase 2/3 Clinical Trials |
| Bone Marrow Failure | Targeted Molecular Interventions | Investigational Research |
- Develop transformative therapies for rare hematologic conditions
- Advance precision medicine approaches
- Minimize treatment-related complications
Pipeline Development Strategy
Keros Therapeutics focuses on developing therapeutics targeting: - Transfusion-dependent thalassemia - Myelodysplastic syndromes - Bone marrow failure disorders
Key Program Metrics| Program | Current Status | Clinical Stage |
|---|---|---|
| KER-050 | Active Development | Phase 2 |
| KER-047 | Investigational | Preclinical |
Financial Investment in Vision
As of Q4 2023, Keros Therapeutics reported: - Research & Development Expenses: $48.3 million - Cash and Investments: $312.4 million
Core Values of Keros Therapeutics, Inc. (KROS)
Core Values of Keros Therapeutics, Inc. (KROS)
Innovation and Scientific Excellence
Keros Therapeutics demonstrates commitment to innovation through its focused research in rare hematological and neurological disorders.
| R&D Investment | 2023 Amount |
|---|---|
| Total R&D Expenses | $72.4 million |
| Research Personnel | 42 dedicated scientists |
Patient-Centered Approach
Keros prioritizes developing therapies addressing unmet medical needs.
- Rare disease focus: Transfusion-dependent beta-thalassemia
- Ongoing clinical trials for KER-050 and KER-047
Collaborative Research Ecosystem
Strategic partnerships enhance scientific capabilities.
| Collaboration Partner | Focus Area |
|---|---|
| Moderna | Therapeutic development |
| Massachusetts General Hospital | Clinical research |
Ethical and Transparent Operations
Commitment to regulatory compliance and scientific integrity.
- FDA Fast Track Designation for KER-050
- Adherence to GCP guidelines
Sustainable Growth and Financial Responsibility
| Financial Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $281.9 million |
| Net Loss | $93.7 million |
Keros Therapeutics, Inc. (KROS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.